494 related articles for article (PubMed ID: 29524506)
1. A 17-Gene Genomic Prostate Score Assay Provides Independent Information on Adverse Pathology in the Setting of Combined Multiparametric Magnetic Resonance Imaging Fusion Targeted and Systematic Prostate Biopsy.
Salmasi A; Said J; Shindel AW; Khoshnoodi P; Felker ER; Sisk AE; Grogan T; McCullough D; Bennett J; Bailey H; Lawrence HJ; Elashoff DA; Marks LS; Raman SS; Febbo PG; Reiter RE
J Urol; 2018 Sep; 200(3):564-572. PubMed ID: 29524506
[TBL] [Abstract][Full Text] [Related]
2. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
[TBL] [Abstract][Full Text] [Related]
3. Defining Prostate Cancer at Favorable Intermediate Risk: The Potential Utility of Magnetic Resonance Imaging and Genomic Tests.
Falagario UG; Beksac AT; Martini A; Cumarasamy S; Gupta A; Prasad S; Thulasidass H; Shah QN; Jayaratna I; Lewis S; Rastinehad AR; Taouli B; Cormio L; Carrieri G; Tewari AK
J Urol; 2019 Jul; 202(1):102-107. PubMed ID: 30730408
[TBL] [Abstract][Full Text] [Related]
4. Prostate Cancer Genomic Classifier Relates More Strongly to Gleason Grade Group Than Prostate Imaging Reporting and Data System Score in Multiparametric Prostate Magnetic Resonance Imaging-ultrasound Fusion Targeted Biopsies.
Martin DT; Ghabili K; Levi A; Humphrey PA; Sprenkle PC
Urology; 2019 Mar; 125():64-72. PubMed ID: 30552940
[TBL] [Abstract][Full Text] [Related]
5. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30577397
[TBL] [Abstract][Full Text] [Related]
6. Added Value of Multiparametric Magnetic Resonance Imaging to Clinical Nomograms for Predicting Adverse Pathology in Prostate Cancer.
Rayn KN; Bloom JB; Gold SA; Hale GR; Baiocco JA; Mehralivand S; Czarniecki M; Sabarwal VK; Valera V; Wood BJ; Merino MJ; Choyke P; Turkbey B; Pinto PA
J Urol; 2018 Nov; 200(5):1041-1047. PubMed ID: 29852182
[TBL] [Abstract][Full Text] [Related]
7. Multiparametric Magnetic Resonance Imaging Features Identify Aggressive Prostate Cancer at the Phenotypic and Transcriptomic Level.
Beksac AT; Cumarasamy S; Falagario U; Xu P; Takhar M; Alshalalfa M; Gupta A; Prasad S; Martini A; Thulasidass H; Rai R; Berger M; Hectors S; Jordan J; Davicioni E; Nair S; Haines K; Lewis S; Rastinehad A; Yadav K; Jayaratna I; Taouli B; Tewari A
J Urol; 2018 Dec; 200(6):1241-1249. PubMed ID: 30563651
[TBL] [Abstract][Full Text] [Related]
8. Risk Stratification of Equivocal Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate.
Ullrich T; Quentin M; Arsov C; Schmaltz AK; Tschischka A; Laqua N; Hiester A; Blondin D; Rabenalt R; Albers P; Antoch G; Schimmöller L
J Urol; 2018 Mar; 199(3):691-698. PubMed ID: 28941924
[TBL] [Abstract][Full Text] [Related]
9. Transcriptome Wide Analysis of Magnetic Resonance Imaging-targeted Biopsy and Matching Surgical Specimens from High-risk Prostate Cancer Patients Treated with Radical Prostatectomy: The Target Must Be Hit.
Radtke JP; Takhar M; Bonekamp D; Kesch C; Erho N; du Plessis M; Buerki C; Ong K; Davicioni E; Hohenfellner M; Hadaschik BA
Eur Urol Focus; 2018 Jul; 4(4):540-546. PubMed ID: 28753844
[TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance.
Radtke JP; Kuru TH; Boxler S; Alt CD; Popeneciu IV; Huettenbrink C; Klein T; Steinemann S; Bergstraesser C; Roethke M; Roth W; Schlemmer HP; Hohenfellner M; Hadaschik BA
J Urol; 2015 Jan; 193(1):87-94. PubMed ID: 25079939
[TBL] [Abstract][Full Text] [Related]
11. The Value of PSA Density in Combination with PI-RADS™ for the Accuracy of Prostate Cancer Prediction.
Distler FA; Radtke JP; Bonekamp D; Kesch C; Schlemmer HP; Wieczorek K; Kirchner M; Pahernik S; Hohenfellner M; Hadaschik BA
J Urol; 2017 Sep; 198(3):575-582. PubMed ID: 28373135
[TBL] [Abstract][Full Text] [Related]
12. The Efficacy of Multiparametric Magnetic Resonance Imaging and Magnetic Resonance Imaging Targeted Biopsy in Risk Classification for Patients with Prostate Cancer on Active Surveillance.
Recabal P; Assel M; Sjoberg DD; Lee D; Laudone VP; Touijer K; Eastham JA; Vargas HA; Coleman J; Ehdaie B
J Urol; 2016 Aug; 196(2):374-81. PubMed ID: 26920465
[TBL] [Abstract][Full Text] [Related]
13. Role of Magnetic Resonance Imaging Targeted Biopsy in Detection of Prostate Cancer Harboring Adverse Pathological Features of Intraductal Carcinoma and Invasive Cribriform Carcinoma.
Prendeville S; Gertner M; Maganti M; Pintilie M; Perlis N; Toi A; Evans AJ; Finelli A; van der Kwast TH; Ghai S
J Urol; 2018 Jul; 200(1):104-113. PubMed ID: 29408568
[TBL] [Abstract][Full Text] [Related]
14. Detection of significant prostate cancer with magnetic resonance targeted biopsies--should transrectal ultrasound-magnetic resonance imaging fusion guided biopsies alone be a standard of care?
Delongchamps NB; Lefèvre A; Bouazza N; Beuvon F; Legman P; Cornud F
J Urol; 2015 Apr; 193(4):1198-204. PubMed ID: 25451824
[TBL] [Abstract][Full Text] [Related]
15. Comparison of Transrectal Ultrasound Biopsy to Transperineal Template Mapping Biopsies Stratified by Multiparametric Magnetic Resonance Imaging Score in the PROMIS Trial.
Lovegrove CE; Miah S; El-Shater Bosaily A; Bott S; Brown L; Burns-Cox N; Dudderidge T; Freeman A; Henderson A; Hindley R; Kaplan R; Kirkham A; Oldroyd R; Parker C; Persad R; Punwani S; Rosario D; Shergill I; Winkler M; Emberton M; Ahmed HU
J Urol; 2020 Jan; 203(1):100-107. PubMed ID: 31335254
[TBL] [Abstract][Full Text] [Related]
16. Genomic Prostate Score, PI-RADS™ version 2 and Progression in Men with Prostate Cancer on Active Surveillance.
Kornberg Z; Cowan JE; Westphalen AC; Cooperberg MR; Chan JM; Zhao S; Shinohara K; Carroll PR
J Urol; 2019 Feb; 201(2):300-307. PubMed ID: 30179620
[TBL] [Abstract][Full Text] [Related]
17. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
18. Critical evaluation of magnetic resonance imaging targeted, transrectal ultrasound guided transperineal fusion biopsy for detection of prostate cancer.
Kuru TH; Roethke MC; Seidenader J; Simpfendörfer T; Boxler S; Alammar K; Rieker P; Popeneciu VI; Roth W; Pahernik S; Schlemmer HP; Hohenfellner M; Hadaschik BA
J Urol; 2013 Oct; 190(4):1380-6. PubMed ID: 23608676
[TBL] [Abstract][Full Text] [Related]
19. Impact of Gleason Subtype on Prostate Cancer Detection Using Multiparametric Magnetic Resonance Imaging: Correlation with Final Histopathology.
Truong M; Hollenberg G; Weinberg E; Messing EM; Miyamoto H; Frye TP
J Urol; 2017 Aug; 198(2):316-321. PubMed ID: 28163032
[TBL] [Abstract][Full Text] [Related]
20. Gleason Score Determination with Transrectal Ultrasound-Magnetic Resonance Imaging Fusion Guided Prostate Biopsies--Are We Gaining in Accuracy?
Lanz C; Cornud F; Beuvon F; Lefèvre A; Legmann P; Zerbib M; Delongchamps NB
J Urol; 2016 Jan; 195(1):88-93. PubMed ID: 26165586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
